跳至主要内容
临床试验/NCT05457543
NCT05457543Unknown不适用

Collection of Blood Products for Use in the Development and Validation of Point-of-Care In Vitro Diagnostic Liver Function Test Devices

Group K Diagnostics Inc.1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2022年6月30日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
150
试验地点
1
主要终点
Regression analysis of bilirubin test results

研究概览

简要总结

This is an observational study exploring the performance of a novel point-of-care diagnostic testing platform designed to quantitate the presence of liver function biomarkers such as bilirubin. Blood samples will be collected from participants to further development and validation of the testing platform to support FDA review. The diagnostic device is intended to provide rapid in-office test results using a finger stick of blood, a reaction test device, and a smartphone app.

详细描述

The nature of outpatient diagnostics delays diagnosis and proper treatment due to the need to travel to a sample collection site that is designed for volume testing adding the individual's sample to the testing que. The physical and temporal separation of diagnostic testing from medical office or virtual care visits delays physician decision-making until results are available. Many patients even skip the recommended testing due to time and financial costs.

Many acute and chronic conditions result in disruption of normal liver function. Common prescription and over-the-counter medications also affect liver function when taken over extended periods or at elevated doses. Having multiple rapid, easy-to-use diagnostic tests on a single platform could improve condition diagnosis and medication monitoring by ensuring current test results are available every time and anywhere they could be useful for immediate medical decision-making.

This study will provide fresh blood samples for further development and validation of a novel point-of-care diagnostic testing platform. Tests for liver function biomarkers such as bilirubin, ALT (alanine transaminase), and AST (aspartate aminotransferase) will be characterized and validated using fresh whole blood, freshly prepared serum, and frozen serum. Enrolled participants will have a standard venous and a standard finger stick blood collection. Enrolled participants can return once weekly for blood draws or can chose to have only a single study visit. The study will continue until sufficient data has been generated to support review of the tests by the FDA.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age and older
  • Able to read and understand an informed consent form written in English

排除标准

  • Pregnancy
  • Participated in the present study within the last 6 days
  • Subject is subjectively unwell at the time of enrollment visit
  • Subject previously participated and has asked to be withdrawn from the study

结局指标

主要结局

Regression analysis of bilirubin test results

时间窗: 6 months

Regression and other statistical analyses will be applied to bilirubin tests results to evaluate quantitation linearity, precision, and accuracy relative to a predicate device.

次要结局

  • Sensitivity of image analysis to changes in concentration of test analyte(9 months)

研究者

发起方
Group K Diagnostics Inc.
申办方类型
Industry
责任方
Principal Investigator
主要研究者

Laura M Ferguson, PhD

Chief Scientific Officer

Group K Diagnostics Inc.

研究点 (1)

Loading locations...

相似试验